Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Premier Biomedical Inc (BIEI)

$BIEI Premier Biomedical Retires Convertible Debt Source: InvestorsHub NewsWire El

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
$Pistol Pete$ Member Profile
Member Level 
Followed By 2,002
Posts 208,931
Boards Moderated 82
Alias Born 05/06/14
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/13/2017 5:22:54 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/5/2017 6:05:53 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/21/2017 6:05:02 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/15/2017 6:06:47 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:01:48 AM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 10/16/2017 5:32:24 PM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 10/4/2017 5:31:13 PM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing "InvestorsHub NewsWire" - 8/30/2017 10:29:33 PM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 8/30/2017 5:33:05 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 "InvestorsHub NewsWire" - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code "InvestorsHub NewsWire" - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference "InvestorsHub NewsWire" - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market "InvestorsHub NewsWire" - 8/22/2017 1:27:13 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/21/2017 5:12:40 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/14/2017 5:12:52 PM
Withdrawal of Registration Statement (rw) "Edgar (US Regulatory)" - 7/24/2017 6:03:46 AM
Premier Biomedical, Inc. CEO Letter - July, 2017 "InvestorsHub NewsWire" - 7/17/2017 7:00:00 AM
Premier Biomedical Integrates CBD-Based Pain Relief Products Business; Expands Current and New Product Offerings "InvestorsHub NewsWire" - 7/13/2017 10:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/12/2017 6:12:45 AM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 7/6/2017 12:57:38 PM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 5/26/2017 6:06:30 AM
Withdrawal of Registration Statement (rw) "Edgar (US Regulatory)" - 5/23/2017 5:24:32 PM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/23/2017 5:24:06 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/22/2017 5:17:27 PM
$Pistol Pete$ Member Level  Thursday, 03/02/17 08:03:39 PM
Re: None
Post # of 49781 
$BIEI Premier Biomedical Retires Convertible Debt

Source: InvestorsHub NewsWire

El Paso, Texas - (Uptick Newswire - March 2, 2017) - Premier Biomedical, Inc. (OTCQB: "BIEI") announced today that the principal amounts on their outstanding convertible debts have been retired. The company acknowledged that, although it still needs capital to keep the business going, they will be more judicious in any future financing.

The company has in the past had as many as five lenders at once converting debt, as they struggled to finance their aggressive research programs on PTSD and cancer. The company has since shelved their promising cancer research program and PTSD research until they can acquire a suitable development partner. The company reports they have been in discussion with a number of potential partners with whom their promising patent-pending antibody drug for breast cancer can be developed.

“It is because of the enormous costs of our research that we decided to pivot our attention, temporarily, towards manufacturing and selling pain relief products to generate a revenue stream. We currently are selling what we consider to be the world’s-best 96-hour pain patch and hemp oil roll-on applicator. We plan on introducing four more pain relief products this calendar year,” said William A. Hartman, President and CEO of Premier Biomedical. The company sells their pain relief products through their website,, as well as through direct distributors.

Hartman continued, “Our stock has been under enormous pressure due to the heavy amount of debt converted into shares and introduced to the market. The dilution of the stock has been a concern to us and all of our shareholders, and to see it reach an end is a relief to us all. Going forward, we will still need to finance a portion of our operations, but we have tightened our belts and will continue to run very lean, until we can generate sufficient revenue to become self-funding. We are confident that our approach will result in a significant increase in our stock price in the future.”

For more information please contact:

William A. Hartman
President and CEO
(724) 633-7033

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website:

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: Uptick Newswire$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist